ABBISKO CAYMAN DL-00001 Market Cap ($566.33 Million)
Market Cap & Net Worth: ABBISKO CAYMAN DL-00001 (8ZD)
ABBISKO CAYMAN DL-00001 market cap. ABBISKO CAYMAN DL-00001 (F:8ZD) has a market capitalization of $566.33 Million (€484.41 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #11270 globally and #1294 in its home market, demonstrating a -13.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABBISKO CAYMAN DL-00001's stock price €0.73 by its total outstanding shares 663578350 (663.58 Million). Also see ABBISKO CAYMAN DL-00001 cash conversion from operations for how efficiently the company converts equity into cash flow.
ABBISKO CAYMAN DL-00001 Market Cap History (2021–2026)
ABBISKO CAYMAN DL-00001 market cap history from 2021 to 2026. Data shows change from $748.64 Million to $566.33 Million (-9.19% CAGR). Check 8ZD stock price for real-time trading data and today's change.
ABBISKO CAYMAN DL-00001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABBISKO CAYMAN DL-00001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ABBISKO CAYMAN DL-00001 equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.74x
ABBISKO CAYMAN DL-00001's market cap is 1.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
19.24x
ABBISKO CAYMAN DL-00001's market cap is 19.24 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $748.64 Million | $22.68 Million | -$1.81 Billion | 33.01x | N/A |
| 2023 | $327.38 Million | $19.06 Million | -$431.58 Million | 17.18x | N/A |
| 2024 | $407.29 Million | $503.99 Million | $28.30 Million | 0.81x | 14.39x |
| 2025 | $1.06 Billion | $612.12 Million | $55.25 Million | 1.74x | 19.24x |
Competitor Companies of 8ZD by Market Capitalization
Companies near ABBISKO CAYMAN DL-00001 in the global market cap rankings as of November 4, 2026. Also see ABBISKO CAYMAN DL-00001 assets under control for a full breakdown of the balance sheet.
Key companies related to ABBISKO CAYMAN DL-00001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ABBISKO CAYMAN DL-00001 (2021–2026)
Market capitalization of ABBISKO CAYMAN DL-00001 from 2021 to today. Between 2021 and today, ABBISKO CAYMAN DL-00001's market cap moved from $748.64 Million to $ 566.33 Million, with a yearly change of -9.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €566.33 Million | -46.72% |
| 2025 | €1.06 Billion | +160.95% |
| 2024 | €407.29 Million | +24.41% |
| 2023 | €327.38 Million | +6.57% |
| 2022 | €307.21 Million | -58.96% |
| 2021 | €748.64 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ABBISKO CAYMAN DL-00001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $566.33 Million USD |
| MoneyControl | $566.33 Million USD |
| MarketWatch | $566.33 Million USD |
| marketcap.company | $566.33 Million USD |
| Reuters | $566.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus … Read more